Darbepoetin alfa

Drug Profile

Darbepoetin alfa

Alternative Names: Aranesp; Darbepoetin-α; KRN-321; Nesp; Nespo; Novel erythropoiesis stimulating protein

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Kirin-Amgen
  • Developer Amgen; Kirin-Amgen; Kyowa Hakko Kirin
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaemia
  • Phase III Breast cancer

Most Recent Events

  • 03 Dec 2016 Efficacy data from the phase III Arcade trial in Anaemia presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
  • 21 Oct 2016 Preregistration for Anaemia (In patients with renal failure) in Indonesia (SC) (Kyowa Hakko Kirin pipeline, October 2016)
  • 21 Oct 2016 Kirin Amgen files applications for Anaemia (In patients with myelodysplastic syndromes) in Malaysia, Hong Kong and Singapore (Kyowa Hakko Kirin pipeline, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top